Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of GSK2402968 in ambulant Duchenne muscular dystrophy subjects amenable to exon 51 skipping
2010-018412-32Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2010
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of drisapersen in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by GSK. Primary endpoint: Primary efficacy endpoint. Started Mar 2010; status: completed.
02
Drugs
drisapersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2010-018412-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018412-32.